- Preliminary 12-week data from the Phase 2 portion of the Phase 2/3 CARDINAL study assessing Reata Pharmaceuticals' (RETA -0.2%) bardoxolone methyl for the treatment of chronic kidney disease (CKD) caused by Alport syndrome showed a statistically significant improvement in kidney function as measured by estimated glomerular filtration rate (eGFR). The results were presented at Kidney Week in New Orleans, LA.
- The increases in eGFR translated to an improvement in CKD stage in 73% (n=22/30) of patients. The results are consistent with those reported in July.
- Management will host a conference call on Monday, November 6 at 8:30 am ET to discuss the results.
- Bardoxolone methyl is an experimental oral once-daily antioxidant inflammation modulator that targets the Nrf2 pathway, a regulator of antioxidant proteins that protect against oxidative damage associated with injury or inflammation.
- Alport syndrome is an inherited disorder characterized by the progressive loss of kidney function.
- Previously: Reata's bardoxolone methyl shows treatment effect in mid-stage kidney disease study; shares ahead 20% (July 24)